Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
The patient took three doses of Vivotif and had no time to pick up the last dose; Case reference number US-BN-2024-002906 is a spontaneous case initially received from a pharmacist via Med Communications (reference number: USBAV24-3339) on 30-Dec-2024 and concerns a female patient of unknown age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient, the patient took first and second dose of Vivotif (batch number: unknown), at unknown dose, route for unknown indication. On 15-Dec-2024, unknown time after first dose of Viviotif, the patient took third dose of Vivotif (batch number: unknown), at unknown dose, route and site of administration. As reported, the patient had not time to pick up the last dose of Vivotif (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241218-390b27 to US-BAVARIAN NORDIC A/S-US-BN-2024-002906, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient of unknown age had not time to pick up the last dose of Vivotif for unknown indication, after the patient took three doses, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unknown age had not time to pick up the last dose of Vivotif for unknown indication, after the patient took three doses, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.